GeoInvesting is taking a bigger interest in looking for opportunities in Canada. But we are aware that Canada can house notorious pump and dump promotions. Breathtec Biomedical is the latest Pump and Dump to enter our radar.
Breathtec Biomedical Pumped by Paragon
It has been a while since we have tracked the penny stock pump and dump environment because many of the major players that pushed P&D names to over $1.00 per share had taken a break from the promotional activity, probably as a result of increased regulatory scrutiny. It seems that legacy third party promoters may be getting back into the game. We have received a pump and dump campaign from The Paragon Report, an outfit that was heavily compensated and responsible for multiple campaigns in the past.
We will continue to monitor the progress of this Breathtec Biomedical promotional campaign initiated by Paragon.
Breathtec Biomedical Inc. Announces Breaking News Today!
Breathtec Biomedical Announces Prof. Hossam Haick as Consultant
Highly recognized and awarded expert to guide trials and approvals process of Na-NOSE Technology.
Breathtec Biomedical, Inc. (CSE: BTH) (CNSX: BTH) (XFRA: BTI) (OTC: BTHCF) (the “Company” or “Breathtec”), a medical diagnostics company focused on developing, and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases is pleased to announce that Professor Hossam Haick of Technion University and the developer of the NA-NOSE disease detection sensors has joined Breathtec Biomedical as consultant. Prof. Haick will guide the company’s development of the NA-NOSE disease detection system and design the clinical trials to be undertaken by the company.
As recently announced, Breathtec entered into a licensing agreement on April 11, 2016 with the Technion Research and Development Foundation Ltd., an Israeli private company and wholly-owned subsidiary of the Technion — Israel Institute of Technology, with respect to a non-exclusive license to certain Technion patents and related know-how in connection with the NA-NOSE disease detection sensors and the detection of the following indications from exhaled breath: Streptococcus; Methicillin resistant (MRSA); Staphylococcus; Enterococcus; Vancomycin resistant (VRE); Pneumococcus; Hemophilus influenza (HiB); Chickenpox; and the common cold.
Prof. Hossam Haick of the Technion Institute
Dr. Haick’s groundbreaking research has led to the creation of a technology that can smell out cancer and other diseases, has recently been acclaimed as one of the world’s most “Good” people, as noted by GOOD Magazine, an international publication that recognizes researchers for the benefits of their work for humanity. According to the magazine publishers, Haick is one of the 100 most influential people in the world who are changing the world in a positive manner. The GOOD 100 are “spearheading change” in the areas of science, education, and business, said the magazine, and Haick, among them, “refuses to accept the existing reality as the end of the story. Not one of the 100 people we have chosen operates out of a desire for fame — which is precisely why it is important to recognize their activity.”
Besides the GOOD recognition, Dr. Haick was also recently presented with the Humboldt Research Award, which recognizes top research done throughout the world in cooperation with research institutes in Germany. Awarded by the Alexander von Humboldt Foundation, the prize is given to prominent researchers who have significantly influenced their fields of study in cooperation with research institutes in Germany. It is granted in recognition of a researcher’s achievements as a whole — discoveries, theories, and insights.
Dr. Haick is best known for developing the Na-NOSE technology that can be used to detect cancer by mechanically “smelling” elements in the breath of potential sufferers. Cancer tumors produce chemicals called volatile organic compounds (VOCs), which easily evaporate into the air and produce a discernible scent profile. Haick’s Na-NOSE chip detects the unique “signature” of VOCs in exhaled breath. In four out of five cases, the device differentiated between benign and malignant lung lesions and even different cancer subtypes.
Mr. Kal Malhi, President of Breathtec Biomedical states, “We are extremely grateful to have acquired the Na-NOSE technology and the guidance of Prof. Haick. He is truly a pioneer in the field of breath testing and has achieved some amazing results in the field. Breathtec is excited to partner with Prof. Haick in order to commercialize breath testing technology and prepare it for a global marketplace.”
ON BEHALF OF THE BOARD
“Kal Malhi” President & Director
New Featured Company
BreathTec Biomedical Inc. Trading Symbol: (America: BTHCF) (Canada: BTH) (Frankfurt: BTI)
Members, we need to focus on this news. We first introduced Breathtec Biomedical Inc. to you before the announcement of the Company In-Licensing the advanced stage Na-Nose breath analysis technology and before today’s news of bringing on Prof. Hossam Haick as a scientific consultant to Breathtec. These two sets of news are potential game changers for the company. Let’s discuss why:
Lung cancer is the number one cause of cancer death, regardless of gender or ethnicity. Unfortunately, diagnosing lung cancer involves extensive imaging, biopsies, and sputum cytology, which aren’t performed until after the patient becomes symptomatic. However, a new diagnostic tool could diagnose lung cancer in a much less invasive fashion, using only a sample of the patient’s breath. The research was presented at the meeting of the American Society for Clinical Oncology in Chicago.
The device is called Nanoscale Artificial NOSE (NA-NOSE) and uses gold nanoparticles to detect compounds in the breath that indicate lung cancer. Not only that, but it could also detect how advanced the disease is. This device was inspired by the ability of dogs, fruit flies, and other organisms to “sniff out” disease.
In one of the most recent studies, the device was tested on 80 individuals with lung cancer and 31 people with chronic obstructive pulmonary disease (COPD). COPD is non-cancerous, but can impede breathing and lead to a persistent cough.
NA-NOSE was able to correctly differentiate between those with lung cancer and those with COPD for about 85 percent of the trials. It was also 79 percent accurate in determining the stage of the cancer. Other studies with the device have shown similar results.
While some at a higher risk for developing lung cancer have received yearly CT screenings, the images are unable to determine cancerous growths versus those that are benign. This results in a great deal of false positives which are only ruled out later after more invasive testing has been completed. While this method does catch more cases of lung cancer, it also puts a tremendous amount of stress on those who don’t have cancer, as well as taking up their time and money.
Over the span of five years, it is estimated that yearly CT screenings will cost the cash-strapped Medicare 9.3 billion dollars!
In the future, NA-NOSE could provide similar early detection screening as CT at a much cheaper rate with fewer false positives. Results would also be available almost immediately, and will not require a physician to be specialized in order to operate the device or interpret the results. The patient would merely blow up a balloon, which the medical professional would then take and run through the device, which is about the size of a desktop computer.
The researchers behind NA-NOSE claim that the applications of the device can extend beyond detection of lung cancer. It could also be used to detect other medical maladies, have uses in homeland security, and monitoring compounds in the environment as well.
Prof. Hossam Haick of the Technion received the Humboldt Research Award in Germany. In addition, Prof. Haick was selected as one of the 100 influential figures published by the American GOOD Magazine
Prof. Hossam Haick of the Technion received the Humboldt Research Award, awarded by the Alexander von Humboldt Foundation in Germany. The award is given to prominent researchers who have significantly influenced their fields of study, provided they maintain some type of cooperation with research institutes in Germany. It is granted in recognition of a researcher’s achievements as a whole — discoveries, theories, and insights.
Prof. Haick, a member of the Wolfson Faculty of Chemical Engineering and a member of the Technion’s Russell Berrie Nanotechnology Institute, received the award for his tremendous contribution to the diagnosis of diseases through innovative markers that he discovered in his research at Technion. These are markers that are present in the breath and skin.
At the same time as the announcement about the Humboldt Research Award, Prof. Haick was included in the list of the world’s 100 most influential people published this week by GOOD Magazine in Los Angeles. The list includes people from 37 countries who contribute to the welfare of humankind in various aspects, including science, education, and business. What they all have in common, according to the list’s compilers, is that they are figures “who spearhead change and refuse to accept the existing reality as the end of the story. Not one of the 100 people we have chosen operates out of a desire for fame — which is precisely why it is important to recognize their activity.”
Prof. Haick will guide BreathTec’s development of the NA-NOSE disease detection system and design the clinical trials to be undertaken by the company!
Prof. Hossam Haick earned his doctorate in the field of energy and only later switched to biomedical technology. He said, “Precisely because I am not a doctor I was able to conceive such a unique development — an inexpensive and noninvasive system for diagnosing diseases based on breath. Inspired by dogs, who know how to identify disease but not to tell the person what disease he has, I developed this digital system that accurately diagnoses the disease and its stage of development. Today, we are working on several aspects of the system, including diagnosis of additional diseases and an interface that connects it to a smartphone.”
New Featured Company
BreathTec Biomedical Inc. Trading Symbol: (America: BTHCF) (Canada: BTH) (Frankfurt: BTI)
Members, today is the day to research our new featured company Breathtec Biomedical Inc. (BTHCF). BTHCF has raised over 3.5 million dollars to-date and recently completed its IPO. Breathtec Biomedical Inc. aims to propel development and commercialization of breath analysis screening technologies. The Company holds an option to acquire key University of Florida patent U.S. 8,237,118 entitled “Partial Ovoidal FAIMS Electrode.” The Company’s management team is comprised of credible professionals including three Ph.D scientists, two of which are from the University of Florida and are leaders in the breath analysis space. The main individual responsible for the development of the FAIMS technology is Dr. Richard A. Yost whom has received over USD 40 million in research grants and has published over 160 papers and 16 patents. Over USD 30 billion worth of instruments have been sold based on these patents. Most important, BTHCF is not putting all its eggs in one basket. As of April 11, 2016 the company has signed a licensing agreement with Technion — Israel Institute of Technology with respect to certain Technion patents and related know-how as it relates to exhaled breath. This agreement gives Breathtec a two prong attack plan. While they are developing the University of Florida miniature FAIMS prototype they can push forward with a technology that already has millions of R&D dollars behind it. This gives Breathtec the ability to rapidly advance the NA-NOSE technology through clinical trials and regulatory approval in North America. The individual who developed the NA-NOSE technology at Technion — Israel Institute of Technology is respected doctor and scientist Prof. Hossam Haick who, as of today, has been brought on to the Breathtec team as a Scientific Consultant. He is an expert in the field of nanotechnology and non-invasive disease diagnosis. Prof. Haick has received almost four dozen prizes for his research including the “Bill & Melinda Gates” award. Prof. Haick has published more than 170 publications in top-level journals and holds more than 28 patents for his inventions.
Can you see the opportunity here? Early investors in BTHCF stand to make a potential fortune as the company continues to make huge corporate developments aimed at important global initiatives. Breathtec Biomedical Inc. is at the forefront of breath analysis technology and the company is well on its way to being a key player in this space. With last week’s news regarding the Na-Nose Technology acquisition and today’s announcement of the Company bringing on Prof. Hossam Haick, there couldn’t be a better time to be an early shareholder in this company. Do not delay, research BTHCF right now!
The Paragon Team
Disclaimer: GeoInvesting is providing this information for your edification and in no way has any affiliation with any promoters and/or newsletters disseminating information on BTHCF, nor is GeoInvesting being paid to post this information. At times, the GeoTeam may trade P&D’s on a long or short basis, depending on how we feel the momentum of the stocks will be affected by the efforts of stock promoters and any ensuing dumps.